Evidence map›Paper›PMID 38201460›Full record

ReviewCancers2023

Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.

Liz Clark, Geoff Fisher, Sue Brook, Sital Patel, Hendrik-Tobias Arkenau

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liz ClarkEllipses Pharma, London W1J 8LG, UK.
Geoff FisherEllipses Pharma, London W1J 8LG, UK.
Sue BrookEllipses Pharma, London W1J 8LG, UK.ORCID 0000-0001-6506-9365
Sital PatelEllipses Pharma, London W1J 8LG, UK.
Hendrik-Tobias ArkenauEllipses Pharma, London W1J 8LG, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RET is a receptor tyrosine kinase that plays an important role in the development of neurons and kidneys. The gene encoding the rearranged-during-transfection (

Indexed as

next-generation selective RET inhibitor (SRI)non-small-cell lung cancer (NSCLC)pralsetinibRET fusionsRET mutationsselpercatinibthyroid cancer

Identifiers

PMID38201460
PMCPMC10778005
OpenAlexW4389995384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.